Adele M. Gulfo

Insider Reports History

Reporting-owner location: Charlotte, NC
Latest reporting-owner signature: /s/ Ali D. Fawaz, Attorney-in-Fact
Transaction source note: Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Adele M. Gulfo

Form 4 holding Director

Enpro Inc.

Security class: Common Stock
Shares / value: 4,860
Estimated value: $1,199,982
Report date: 12 Feb 2026
Price: $246.91
Ownership: Direct

Form 4 holding Director

Enpro Inc.

Security class: Phantom Stock
Shares / value: 5,272
Estimated value: $1,127,751
Report date: 18 Mar 2026
Price: $214.13
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding Director

Tyra Biosciences, Inc.

Security class: Common Stock (Right to Buy)
Shares / value: 37,200
Estimated value: $604,961
Report date: 29 Jan 2025
Price: $16.26
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding Director

NewAmsterdam Pharma Co N.V.

Security class: Ordinary Shares
Shares / value: 14,260
Estimated value: $500,457
Report date: 07 Jan 2026
Price: $35.10
Ownership: Direct

Form 4 holding Director

Tyra Biosciences, Inc.

Security class: Common Stock
Shares / value: 4,000
Estimated value: $65,050
Report date: 29 Jan 2025
Price: $16.26
Ownership: Direct

Form 4 holding Director

NewAmsterdam Pharma Co N.V.

Security class: Option (right to buy)
Shares / value: 15,300
Estimated value
Report date: 07 Jan 2026
Price
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount

Form 4 holding Director

Tyra Biosciences, Inc.

Security class: Stock Option (Right to Buy)
Shares / value: 13,160
Estimated value
Report date: 28 May 2026
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding Director

Myovant Sciences Ltd.

Security class: Common Shares
Shares / value: 0
Estimated value
Report date: 10 Mar 2023
Price: $27.00
Ownership: Direct

Form 4 holding Director

Myovant Sciences Ltd.

Security class: Stock Options (Right to Buy)
Shares / value: 0
Estimated value
Report date: 10 Mar 2023
Price
Ownership: Direct
Underlying class: Common Shares
Underlying amount

Insider Reports Filed by Adele M. Gulfo

4 TYRA

Tyra Biosciences, Inc.

Report period: 28 May 2026
Transactions: 1
Transaction value: $0
Accepted by SEC: 01 Jun 2026, 16:30
Role: Director
Next action: Open filing details

4 NPO

Enpro Inc.

Report period: 18 Mar 2026
Transactions: 2
Transaction value: $0
Accepted by SEC: 19 Mar 2026, 14:47
Role: Director
Next action: Open filing details

4 NPO

Enpro Inc.

Report period: 12 Feb 2026
Transactions: 1
Transaction value: +$139,998
Accepted by SEC: 12 Feb 2026, 17:51
Role: Director
Next action: Open filing details

4 NAMS

NewAmsterdam Pharma Co N.V.

Report period: 07 Jan 2026
Transactions: 2
Transaction value: $0
Accepted by SEC: 09 Jan 2026, 19:34
Role: Director
Next action: Open filing details

4 NPO

Enpro Inc.

Report period: 31 Dec 2025
Transactions: 1
Transaction value: +$25,000
Accepted by SEC: 05 Jan 2026, 13:29
Role: Director
Next action: Open filing details

4 NPO

Enpro Inc.

Report period: 17 Dec 2025
Transactions: 2
Transaction value: +$1,354
Accepted by SEC: 18 Dec 2025, 13:59
Role: Director
Next action: Open filing details

4 NPO

Enpro Inc.

Report period: 30 Sep 2025
Transactions: 1
Transaction value: +$25,000
Accepted by SEC: 01 Oct 2025, 15:02
Role: Director
Next action: Open filing details

4 NPO

Enpro Inc.

Report period: 17 Sep 2025
Transactions: 2
Transaction value: +$1,396
Accepted by SEC: 18 Sep 2025, 14:19
Role: Director
Next action: Open filing details

4 NPO

Enpro Inc.

Report period: 30 Jun 2025
Transactions: 1
Transaction value: +$25,000
Accepted by SEC: 01 Jul 2025, 14:12
Role: Director
Next action: Open filing details

4 NPO

Enpro Inc.

Report period: 18 Jun 2025
Transactions: 2
Transaction value: +$1,349
Accepted by SEC: 20 Jun 2025, 14:13
Role: Director
Next action: Open filing details

4 NAMS

NewAmsterdam Pharma Co N.V.

Report period: 15 Apr 2025
Transactions: 2
Transaction value: $0
Accepted by SEC: 17 Apr 2025, 17:36
Role: Director
Next action: Open filing details

3 NAMS

NewAmsterdam Pharma Co N.V.

Report period: 15 Apr 2025
Transactions: 0
Transaction value: $0
Accepted by SEC: 17 Apr 2025, 17:34
Role: Director
Next action: Open filing details

4 NPO

Enpro Inc.

Report period: 31 Mar 2025
Transactions: 1
Transaction value: +$25,000
Accepted by SEC: 01 Apr 2025, 14:50
Role: Director
Next action: Open filing details

4 NPO

Enpro Inc.

Report period: 19 Mar 2025
Transactions: 1
Transaction value: +$1,230
Accepted by SEC: 20 Mar 2025, 14:21
Role: Director
Next action: Open filing details

4 NPO

Enpro Inc.

Report period: 13 Feb 2025
Transactions: 1
Transaction value: +$124,855
Accepted by SEC: 13 Feb 2025, 15:41
Role: Director
Next action: Open filing details

4 TYRA

Tyra Biosciences, Inc.

Report period: 29 Jan 2025
Transactions: 1
Transaction value: $0
Accepted by SEC: 31 Jan 2025, 16:10
Role: Director
Next action: Open filing details

3 TYRA

Tyra Biosciences, Inc.

Report period: 29 Jan 2025
Transactions: 0
Transaction value: $0
Accepted by SEC: 31 Jan 2025, 16:05
Role: Director
Next action: Open filing details

4 NPO

Enpro Inc.

Report period: 18 Dec 2024
Transactions: 1
Transaction value: +$1,231
Accepted by SEC: 19 Dec 2024, 13:20
Role: Director
Next action: Open filing details

4 NPO

Enpro Inc.

Report period: 18 Sep 2024
Transactions: 1
Transaction value: +$1,254
Accepted by SEC: 19 Sep 2024, 16:48
Role: Director
Next action: Open filing details

4 NPO

Enpro Inc.

Report period: 20 Jun 2024
Transactions: 1
Transaction value: +$1,175
Accepted by SEC: 24 Jun 2024, 15:35
Role: Director
Next action: Open filing details

4 NPO

Enpro Inc.

Report period: 20 Mar 2024
Transactions: 1
Transaction value: +$1,278
Accepted by SEC: 21 Mar 2024, 16:12
Role: Director
Next action: Open filing details

4 NPO

Enpro Inc.

Report period: 15 Feb 2024
Transactions: 1
Transaction value: +$124,995
Accepted by SEC: 15 Feb 2024, 16:37
Role: Director
Next action: Open filing details

4 NPO

Enpro Inc.

Report period: 13 Dec 2023
Transactions: 1
Transaction value: +$1,124
Accepted by SEC: 14 Dec 2023, 16:36
Role: Director
Next action: Open filing details

4 NPO

ENPRO INDUSTRIES, INC

Report period: 13 Sep 2023
Transactions: 1
Transaction value: +$1,115
Accepted by SEC: 14 Sep 2023, 16:09
Role: Director
Next action: Open filing details

4 NPO

ENPRO INDUSTRIES, INC

Report period: 14 Jun 2023
Transactions: 1
Transaction value: +$1,131
Accepted by SEC: 15 Jun 2023, 17:11
Role: Director
Next action: Open filing details

4 NPO

ENPRO INDUSTRIES, INC

Report period: 15 Mar 2023
Transactions: 1
Transaction value: +$1,151
Accepted by SEC: 16 Mar 2023, 16:38
Role: Director
Next action: Open filing details

4

Myovant Sciences Ltd.

Report period: 10 Mar 2023
Transactions: 4
Transaction value: $0
Accepted by SEC: 10 Mar 2023, 08:28
Role: Director
Next action: Open filing details

4 NPO

ENPRO INDUSTRIES, INC

Report period: 16 Feb 2023
Transactions: 1
Transaction value: +$109,922
Accepted by SEC: 17 Feb 2023, 11:26
Role: Director
Next action: Open filing details

4 NPO

ENPRO INDUSTRIES, INC

Report period: 14 Dec 2022
Transactions: 1
Transaction value: +$1,079
Accepted by SEC: 15 Dec 2022, 14:27
Role: Director
Next action: Open filing details

4

Myovant Sciences Ltd.

Report period: 26 Oct 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 28 Oct 2022, 16:38
Role: Director
Next action: Open filing details

4 NPO

ENPRO INDUSTRIES, INC

Report period: 14 Sep 2022
Transactions: 1
Transaction value: +$1,083
Accepted by SEC: 15 Sep 2022, 15:14
Role: Director
Next action: Open filing details

4 NPO

ENPRO INDUSTRIES, INC

Report period: 15 Jun 2022
Transactions: 1
Transaction value: +$1,138
Accepted by SEC: 16 Jun 2022, 14:28
Role: Director
Next action: Open filing details

4 NPO

ENPRO INDUSTRIES, INC

Report period: 16 Mar 2022
Transactions: 1
Transaction value: +$1,065
Accepted by SEC: 17 Mar 2022, 15:59
Role: Director
Next action: Open filing details

4 NPO

ENPRO INDUSTRIES, INC

Report period: 15 Feb 2022
Transactions: 1
Transaction value: +$109,971
Accepted by SEC: 16 Feb 2022, 13:13
Role: Director
Next action: Open filing details

4 NPO

ENPRO INDUSTRIES, INC

Report period: 15 Dec 2021
Transactions: 1
Transaction value: +$1,062
Accepted by SEC: 16 Dec 2021, 16:19
Role: Director
Next action: Open filing details

4

Myovant Sciences Ltd.

Report period: 05 Nov 2021
Transactions: 1
Transaction value: $0
Accepted by SEC: 09 Nov 2021, 16:36
Role: Director
Next action: Open filing details

4 NPO

ENPRO INDUSTRIES, INC

Report period: 15 Sep 2021
Transactions: 1
Transaction value: +$1,078
Accepted by SEC: 17 Sep 2021, 16:06
Role: Director
Next action: Open filing details

4 NPO

ENPRO INDUSTRIES, INC

Report period: 16 Jun 2021
Transactions: 1
Transaction value: +$1,082
Accepted by SEC: 17 Jun 2021, 15:43
Role: Director
Next action: Open filing details

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .